Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CTSK | P43235 | 7/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7932040 | 1.00 | CTSL (0.46) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL12047518 | 0.96 | CTSL (0.41) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL22213480 | 0.91 | GRIN2B (0.38) | — | |
| SCHEMBL17070985 | 0.87 | GRIN2B (0.40) | — | |
| SCHEMBL16646195 | 0.85 | GRIN2B (0.41) | — | |
| SCHEMBL17030274 | 0.85 | GRIN2B (0.41) | — | |
| SCHEMBL12028815 | 0.84 | — | — | |
| SCHEMBL18538176 | 0.83 | HTT (0.37) | RAB9A | |
| SCHEMBL17281441 | 0.83 | CCR1 (0.50) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL12028816 | 0.82 | SLC15A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802946-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802946-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9593145-B2 | Secondary structure stabilized NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593145-B2 | Secondary structure stabilized NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9512133-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512133-B2 | NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160115197-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2016-04-28 | — | — | US | disclosed |
| US-20160115197-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2016-04-28 | — | — | US | disclosed |
| US-20150336969-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336969-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2331571-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | UNIV NORTHWESTERN (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9101612-B2 | Secondary structure stabilized NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101612-B2 | Secondary structure stabilized NMDA receptor modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
| US-20130053325-A1 | Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053325-A1 | Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-28 | — | — | US | disclosed |
| US-20110306586-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011100585-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | MOSKAL JOSEPH (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2010033757-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336969-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSL 4016/4885CTSS 4517/4885CTSK 3566/4885 |
| US-20130053325-A1 | Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof | GRIN2A, GRIN1, GRIN3A | CTSL 4593/4885CTSS 4529/4885CTSK 4221/4885 |
| US-20150105364-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSL 4016/4885CTSS 4517/4885CTSK 3566/4885 |
| US-20110306586-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSL 4016/4885CTSS 4517/4885CTSK 3566/4885 |
| US-20160115197-A1 | SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2A, GRIN1, GRIN3A | CTSL 4593/4885CTSS 4529/4885CTSK 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.